Global Antibody Drug Conjugate research

Antibody Drug Conjugate Comprehensive Study by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor), Conjugates (Small Molecules, Protein Toxin, Cytolytic Immunomodulatory Protein, Biologically Active Peptide, Enzymes, Radionuclides), Linker (Cleavable Linker, Non-Cleavable Linker), Route Of Administration (Enteral Route, Parenteral Route), Indications (Breast Cancer, Lymphoma (Hl, Nhl, Alcl), Leukemia (Aml, All), Urothelial Cancer, Lung Cancer (Nsclc, SCLC),, Others) Players and Region - Global Market Outlook to 2030

Antibody Drug Conjugate Market by XX Submarkets | Forecast Years 2022-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Antibody Drug Conjugate
Over the years, a number of companies(small or well-funded start-ups), offering novel conjugation technologies, more potent warheads, and advanced linker technologies, have been established. Moreover, the multiple collaborations licensing agreements, have been inked in the past few years between technology providers and drug developers to advance the development of pipeline Antibody Drug Conjugate candidates. Antibody-Drug Conjugates is a matter made up of a monoclonal antibody chemically linked to a drug. The monoclonal antibody binds to specific proteins on certain types of cells, such as cancer cells. These drug enters these cells and kills them without harming other cells. Some antibody-drug conjugates are used to treat cancer. Also called ADC. According to the research done by the World Health Organization, in 2018 some 18 million people around the world were diagnosed with cancer and some 9.6 million died of the disease. Cancers of the digestive organs, lungs are more common, affecting both men and women, while breast and cervical cancer are naturally prevalent among women. The growing popularity and therapeutic possiblity of Antibody Drug Conjugate can also be correlated with an exponential rise in the number of patents that have been granted

AttributesDetails
Study Period2018-2030
Base Year2021
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Antibody Drug Conjugate market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer (United States), Progenics Pharmaceuticals(United States), Novartis (Switzerland), Eli Lilly(United States), Genentech(United States), Genmab (Denmark), Amgen (United States), Bayer HealthCare (Germany), Celldex Therapeutics(United States) and Concortis Biotherapeutics(United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Mersana Therapeutics(United States), Millennium Pharmaceuticals(United States), AbbVie (United States) and Agensys(United States).

Segmentation Overview
AMA Research has segmented the market of Global Antibody Drug Conjugate market by , Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer and Brain Tumor) and Region.



On the basis of geography, the market of Antibody Drug Conjugate has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Conjugates, the sub-segment i.e. Small Molecules will boost the Antibody Drug Conjugate market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Linker, the sub-segment i.e. Cleavable Linker will boost the Antibody Drug Conjugate market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route Of Administration, the sub-segment i.e. Enteral Route will boost the Antibody Drug Conjugate market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indications, the sub-segment i.e. Breast Cancer will boost the Antibody Drug Conjugate market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Emergence Of Cancer Treatment Options

Market Growth Drivers:
The Growing Geriatric Population Is Expected To Drive Growth Of The Market Over The Forecast Period. and Increasing Incidence Of Cancer Coupled With Growing Geriatric Population

Challenges:
High cost of the treatment

Restraints:
The adverse effect of the treatment

Opportunities:
Innovative Drug Development Opening A New Horizon In Cancer Therapy

Market Leaders and their expansionary development strategies
In September 2020 Gilead’s the United States Based Phamacitiucals Company Has USD 21 Billion Purchase Of Immunomedics Boosts ADC Field.



Key Target Audience
Antibody-Drug Conjugate Providers, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor
By Conjugates
  • Small Molecules
  • Protein Toxin
  • Cytolytic Immunomodulatory Protein
  • Biologically Active Peptide
  • Enzymes
  • Radionuclides

By Linker
  • Cleavable Linker
  • Non-Cleavable Linker

By Route Of Administration
  • Enteral Route
  • Parenteral Route

By Indications
  • Breast Cancer
  • Lymphoma (Hl, Nhl, Alcl)
  • Leukemia (Aml, All)
  • Urothelial Cancer
  • Lung Cancer (Nsclc, SCLC),
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Growing Geriatric Population Is Expected To Drive Growth Of The Market Over The Forecast Period.
      • 3.2.2. Increasing Incidence Of Cancer Coupled With Growing Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. High cost of the treatment
    • 3.4. Market Trends
      • 3.4.1. Emergence Of Cancer Treatment Options
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antibody Drug Conjugate, by Application, Conjugates, Linker, Route Of Administration, Indications and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Antibody Drug Conjugate (Value)
      • 5.2.1. Global Antibody Drug Conjugate by: Application (Value)
        • 5.2.1.1. Blood Cancer
        • 5.2.1.2. Breast Cancer
        • 5.2.1.3. Ovarian Cancer
        • 5.2.1.4. Lung Cancer
        • 5.2.1.5. Brain Tumor
      • 5.2.2. Global Antibody Drug Conjugate by: Conjugates (Value)
        • 5.2.2.1. Small Molecules
        • 5.2.2.2. Protein Toxin
        • 5.2.2.3. Cytolytic Immunomodulatory Protein
        • 5.2.2.4. Biologically Active Peptide
        • 5.2.2.5. Enzymes
        • 5.2.2.6. Radionuclides
      • 5.2.3. Global Antibody Drug Conjugate by: Route Of Administration (Value)
        • 5.2.3.1. Enteral Route
        • 5.2.3.2. Parenteral Route
      • 5.2.4. Global Antibody Drug Conjugate by: Indications (Value)
        • 5.2.4.1. Breast Cancer
        • 5.2.4.2. Lymphoma (Hl, Nhl, Alcl)
        • 5.2.4.3. Leukemia (Aml, All)
        • 5.2.4.4. Urothelial Cancer
        • 5.2.4.5. Lung Cancer (Nsclc, SCLC),
        • 5.2.4.6. Others
      • 5.2.5. Global Antibody Drug Conjugate Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Antibody Drug Conjugate (Volume)
      • 5.3.1. Global Antibody Drug Conjugate by: Application (Volume)
        • 5.3.1.1. Blood Cancer
        • 5.3.1.2. Breast Cancer
        • 5.3.1.3. Ovarian Cancer
        • 5.3.1.4. Lung Cancer
        • 5.3.1.5. Brain Tumor
      • 5.3.2. Global Antibody Drug Conjugate by: Conjugates (Volume)
        • 5.3.2.1. Small Molecules
        • 5.3.2.2. Protein Toxin
        • 5.3.2.3. Cytolytic Immunomodulatory Protein
        • 5.3.2.4. Biologically Active Peptide
        • 5.3.2.5. Enzymes
        • 5.3.2.6. Radionuclides
      • 5.3.3. Global Antibody Drug Conjugate by: Route Of Administration (Volume)
        • 5.3.3.1. Enteral Route
        • 5.3.3.2. Parenteral Route
      • 5.3.4. Global Antibody Drug Conjugate by: Indications (Volume)
        • 5.3.4.1. Breast Cancer
        • 5.3.4.2. Lymphoma (Hl, Nhl, Alcl)
        • 5.3.4.3. Leukemia (Aml, All)
        • 5.3.4.4. Urothelial Cancer
        • 5.3.4.5. Lung Cancer (Nsclc, SCLC),
        • 5.3.4.6. Others
      • 5.3.5. Global Antibody Drug Conjugate Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Antibody Drug Conjugate (Price)
  • 6. Antibody Drug Conjugate: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Progenics Pharmaceuticals(United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Genentech(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genmab (Denmark)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Amgen (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer HealthCare (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Celldex Therapeutics(United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Concortis Biotherapeutics(United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antibody Drug Conjugate Sale, by Application, Conjugates, Linker, Route Of Administration, Indications and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Antibody Drug Conjugate (Value)
      • 7.2.1. Global Antibody Drug Conjugate by: Application (Value)
        • 7.2.1.1. Blood Cancer
        • 7.2.1.2. Breast Cancer
        • 7.2.1.3. Ovarian Cancer
        • 7.2.1.4. Lung Cancer
        • 7.2.1.5. Brain Tumor
      • 7.2.2. Global Antibody Drug Conjugate by: Conjugates (Value)
        • 7.2.2.1. Small Molecules
        • 7.2.2.2. Protein Toxin
        • 7.2.2.3. Cytolytic Immunomodulatory Protein
        • 7.2.2.4. Biologically Active Peptide
        • 7.2.2.5. Enzymes
        • 7.2.2.6. Radionuclides
      • 7.2.3. Global Antibody Drug Conjugate by: Route Of Administration (Value)
        • 7.2.3.1. Enteral Route
        • 7.2.3.2. Parenteral Route
      • 7.2.4. Global Antibody Drug Conjugate by: Indications (Value)
        • 7.2.4.1. Breast Cancer
        • 7.2.4.2. Lymphoma (Hl, Nhl, Alcl)
        • 7.2.4.3. Leukemia (Aml, All)
        • 7.2.4.4. Urothelial Cancer
        • 7.2.4.5. Lung Cancer (Nsclc, SCLC),
        • 7.2.4.6. Others
      • 7.2.5. Global Antibody Drug Conjugate Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Antibody Drug Conjugate (Volume)
      • 7.3.1. Global Antibody Drug Conjugate by: Application (Volume)
        • 7.3.1.1. Blood Cancer
        • 7.3.1.2. Breast Cancer
        • 7.3.1.3. Ovarian Cancer
        • 7.3.1.4. Lung Cancer
        • 7.3.1.5. Brain Tumor
      • 7.3.2. Global Antibody Drug Conjugate by: Conjugates (Volume)
        • 7.3.2.1. Small Molecules
        • 7.3.2.2. Protein Toxin
        • 7.3.2.3. Cytolytic Immunomodulatory Protein
        • 7.3.2.4. Biologically Active Peptide
        • 7.3.2.5. Enzymes
        • 7.3.2.6. Radionuclides
      • 7.3.3. Global Antibody Drug Conjugate by: Route Of Administration (Volume)
        • 7.3.3.1. Enteral Route
        • 7.3.3.2. Parenteral Route
      • 7.3.4. Global Antibody Drug Conjugate by: Indications (Volume)
        • 7.3.4.1. Breast Cancer
        • 7.3.4.2. Lymphoma (Hl, Nhl, Alcl)
        • 7.3.4.3. Leukemia (Aml, All)
        • 7.3.4.4. Urothelial Cancer
        • 7.3.4.5. Lung Cancer (Nsclc, SCLC),
        • 7.3.4.6. Others
      • 7.3.5. Global Antibody Drug Conjugate Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Antibody Drug Conjugate (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antibody Drug Conjugate: by Application(USD Million)
  • Table 2. Antibody Drug Conjugate Blood Cancer , by Region USD Million (2016-2021)
  • Table 3. Antibody Drug Conjugate Breast Cancer , by Region USD Million (2016-2021)
  • Table 4. Antibody Drug Conjugate Ovarian Cancer , by Region USD Million (2016-2021)
  • Table 5. Antibody Drug Conjugate Lung Cancer , by Region USD Million (2016-2021)
  • Table 6. Antibody Drug Conjugate Brain Tumor , by Region USD Million (2016-2021)
  • Table 7. Antibody Drug Conjugate: by Conjugates(USD Million)
  • Table 8. Antibody Drug Conjugate Small Molecules , by Region USD Million (2016-2021)
  • Table 9. Antibody Drug Conjugate Protein Toxin , by Region USD Million (2016-2021)
  • Table 10. Antibody Drug Conjugate Cytolytic Immunomodulatory Protein , by Region USD Million (2016-2021)
  • Table 11. Antibody Drug Conjugate Biologically Active Peptide , by Region USD Million (2016-2021)
  • Table 12. Antibody Drug Conjugate Enzymes , by Region USD Million (2016-2021)
  • Table 13. Antibody Drug Conjugate Radionuclides , by Region USD Million (2016-2021)
  • Table 14. Antibody Drug Conjugate: by Route Of Administration(USD Million)
  • Table 15. Antibody Drug Conjugate Enteral Route , by Region USD Million (2016-2021)
  • Table 16. Antibody Drug Conjugate Parenteral Route , by Region USD Million (2016-2021)
  • Table 17. Antibody Drug Conjugate: by Indications(USD Million)
  • Table 18. Antibody Drug Conjugate Breast Cancer , by Region USD Million (2016-2021)
  • Table 19. Antibody Drug Conjugate Lymphoma (Hl, Nhl, Alcl) , by Region USD Million (2016-2021)
  • Table 20. Antibody Drug Conjugate Leukemia (Aml, All) , by Region USD Million (2016-2021)
  • Table 21. Antibody Drug Conjugate Urothelial Cancer , by Region USD Million (2016-2021)
  • Table 22. Antibody Drug Conjugate Lung Cancer (Nsclc, SCLC), , by Region USD Million (2016-2021)
  • Table 23. Antibody Drug Conjugate Others , by Region USD Million (2016-2021)
  • Table 24. South America Antibody Drug Conjugate, by Country USD Million (2016-2021)
  • Table 25. South America Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 26. South America Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 27. South America Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 28. South America Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 29. South America Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 30. Brazil Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 31. Brazil Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 32. Brazil Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 33. Brazil Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 34. Brazil Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 35. Argentina Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 36. Argentina Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 37. Argentina Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 38. Argentina Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 39. Argentina Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 40. Rest of South America Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 41. Rest of South America Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 42. Rest of South America Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 43. Rest of South America Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 44. Rest of South America Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 45. Asia Pacific Antibody Drug Conjugate, by Country USD Million (2016-2021)
  • Table 46. Asia Pacific Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 47. Asia Pacific Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 48. Asia Pacific Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 49. Asia Pacific Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 50. Asia Pacific Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 51. China Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 52. China Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 53. China Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 54. China Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 55. China Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 56. Japan Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 57. Japan Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 58. Japan Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 59. Japan Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 60. Japan Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 61. India Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 62. India Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 63. India Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 64. India Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 65. India Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 66. South Korea Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 67. South Korea Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 68. South Korea Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 69. South Korea Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 70. South Korea Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 71. Taiwan Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 72. Taiwan Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 73. Taiwan Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 74. Taiwan Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 75. Taiwan Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 76. Australia Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 77. Australia Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 78. Australia Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 79. Australia Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 80. Australia Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 81. Rest of Asia-Pacific Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 82. Rest of Asia-Pacific Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 83. Rest of Asia-Pacific Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 84. Rest of Asia-Pacific Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 85. Rest of Asia-Pacific Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 86. Europe Antibody Drug Conjugate, by Country USD Million (2016-2021)
  • Table 87. Europe Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 88. Europe Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 89. Europe Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 90. Europe Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 91. Europe Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 92. Germany Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 93. Germany Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 94. Germany Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 95. Germany Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 96. Germany Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 97. France Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 98. France Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 99. France Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 100. France Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 101. France Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 102. Italy Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 103. Italy Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 104. Italy Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 105. Italy Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 106. Italy Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 107. United Kingdom Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 108. United Kingdom Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 109. United Kingdom Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 110. United Kingdom Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 111. United Kingdom Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 112. Netherlands Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 113. Netherlands Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 114. Netherlands Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 115. Netherlands Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 116. Netherlands Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 117. Rest of Europe Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 118. Rest of Europe Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 119. Rest of Europe Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 120. Rest of Europe Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 121. Rest of Europe Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 122. MEA Antibody Drug Conjugate, by Country USD Million (2016-2021)
  • Table 123. MEA Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 124. MEA Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 125. MEA Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 126. MEA Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 127. MEA Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 128. Middle East Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 129. Middle East Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 130. Middle East Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 131. Middle East Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 132. Middle East Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 133. Africa Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 134. Africa Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 135. Africa Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 136. Africa Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 137. Africa Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 138. North America Antibody Drug Conjugate, by Country USD Million (2016-2021)
  • Table 139. North America Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 140. North America Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 141. North America Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 142. North America Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 143. North America Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 144. United States Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 145. United States Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 146. United States Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 147. United States Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 148. United States Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 149. Canada Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 150. Canada Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 151. Canada Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 152. Canada Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 153. Canada Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 154. Mexico Antibody Drug Conjugate, by Application USD Million (2016-2021)
  • Table 155. Mexico Antibody Drug Conjugate, by Conjugates USD Million (2016-2021)
  • Table 156. Mexico Antibody Drug Conjugate, by Linker USD Million (2016-2021)
  • Table 157. Mexico Antibody Drug Conjugate, by Route Of Administration USD Million (2016-2021)
  • Table 158. Mexico Antibody Drug Conjugate, by Indications USD Million (2016-2021)
  • Table 159. Antibody Drug Conjugate Sales: by Application(Tons)
  • Table 160. Antibody Drug Conjugate Sales Blood Cancer , by Region Tons (2016-2021)
  • Table 161. Antibody Drug Conjugate Sales Breast Cancer , by Region Tons (2016-2021)
  • Table 162. Antibody Drug Conjugate Sales Ovarian Cancer , by Region Tons (2016-2021)
  • Table 163. Antibody Drug Conjugate Sales Lung Cancer , by Region Tons (2016-2021)
  • Table 164. Antibody Drug Conjugate Sales Brain Tumor , by Region Tons (2016-2021)
  • Table 165. Antibody Drug Conjugate Sales: by Conjugates(Tons)
  • Table 166. Antibody Drug Conjugate Sales Small Molecules , by Region Tons (2016-2021)
  • Table 167. Antibody Drug Conjugate Sales Protein Toxin , by Region Tons (2016-2021)
  • Table 168. Antibody Drug Conjugate Sales Cytolytic Immunomodulatory Protein , by Region Tons (2016-2021)
  • Table 169. Antibody Drug Conjugate Sales Biologically Active Peptide , by Region Tons (2016-2021)
  • Table 170. Antibody Drug Conjugate Sales Enzymes , by Region Tons (2016-2021)
  • Table 171. Antibody Drug Conjugate Sales Radionuclides , by Region Tons (2016-2021)
  • Table 172. Antibody Drug Conjugate Sales: by Route Of Administration(Tons)
  • Table 173. Antibody Drug Conjugate Sales Enteral Route , by Region Tons (2016-2021)
  • Table 174. Antibody Drug Conjugate Sales Parenteral Route , by Region Tons (2016-2021)
  • Table 175. Antibody Drug Conjugate Sales: by Indications(Tons)
  • Table 176. Antibody Drug Conjugate Sales Breast Cancer , by Region Tons (2016-2021)
  • Table 177. Antibody Drug Conjugate Sales Lymphoma (Hl, Nhl, Alcl) , by Region Tons (2016-2021)
  • Table 178. Antibody Drug Conjugate Sales Leukemia (Aml, All) , by Region Tons (2016-2021)
  • Table 179. Antibody Drug Conjugate Sales Urothelial Cancer , by Region Tons (2016-2021)
  • Table 180. Antibody Drug Conjugate Sales Lung Cancer (Nsclc, SCLC), , by Region Tons (2016-2021)
  • Table 181. Antibody Drug Conjugate Sales Others , by Region Tons (2016-2021)
  • Table 182. South America Antibody Drug Conjugate Sales, by Country Tons (2016-2021)
  • Table 183. South America Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 184. South America Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 185. South America Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 186. South America Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 187. South America Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 188. Brazil Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 189. Brazil Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 190. Brazil Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 191. Brazil Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 192. Brazil Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 193. Argentina Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 194. Argentina Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 195. Argentina Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 196. Argentina Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 197. Argentina Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 198. Rest of South America Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 199. Rest of South America Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 200. Rest of South America Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 201. Rest of South America Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 202. Rest of South America Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 203. Asia Pacific Antibody Drug Conjugate Sales, by Country Tons (2016-2021)
  • Table 204. Asia Pacific Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 205. Asia Pacific Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 206. Asia Pacific Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 207. Asia Pacific Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 208. Asia Pacific Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 209. China Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 210. China Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 211. China Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 212. China Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 213. China Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 214. Japan Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 215. Japan Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 216. Japan Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 217. Japan Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 218. Japan Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 219. India Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 220. India Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 221. India Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 222. India Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 223. India Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 224. South Korea Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 225. South Korea Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 226. South Korea Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 227. South Korea Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 228. South Korea Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 229. Taiwan Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 230. Taiwan Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 231. Taiwan Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 232. Taiwan Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 233. Taiwan Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 234. Australia Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 235. Australia Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 236. Australia Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 237. Australia Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 238. Australia Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 239. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 240. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 241. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 242. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 243. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 244. Europe Antibody Drug Conjugate Sales, by Country Tons (2016-2021)
  • Table 245. Europe Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 246. Europe Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 247. Europe Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 248. Europe Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 249. Europe Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 250. Germany Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 251. Germany Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 252. Germany Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 253. Germany Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 254. Germany Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 255. France Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 256. France Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 257. France Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 258. France Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 259. France Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 260. Italy Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 261. Italy Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 262. Italy Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 263. Italy Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 264. Italy Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 265. United Kingdom Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 266. United Kingdom Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 267. United Kingdom Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 268. United Kingdom Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 269. United Kingdom Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 270. Netherlands Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 271. Netherlands Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 272. Netherlands Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 273. Netherlands Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 274. Netherlands Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 275. Rest of Europe Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 276. Rest of Europe Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 277. Rest of Europe Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 278. Rest of Europe Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 279. Rest of Europe Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 280. MEA Antibody Drug Conjugate Sales, by Country Tons (2016-2021)
  • Table 281. MEA Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 282. MEA Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 283. MEA Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 284. MEA Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 285. MEA Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 286. Middle East Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 287. Middle East Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 288. Middle East Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 289. Middle East Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 290. Middle East Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 291. Africa Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 292. Africa Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 293. Africa Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 294. Africa Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 295. Africa Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 296. North America Antibody Drug Conjugate Sales, by Country Tons (2016-2021)
  • Table 297. North America Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 298. North America Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 299. North America Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 300. North America Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 301. North America Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 302. United States Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 303. United States Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 304. United States Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 305. United States Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 306. United States Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 307. Canada Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 308. Canada Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 309. Canada Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 310. Canada Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 311. Canada Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 312. Mexico Antibody Drug Conjugate Sales, by Application Tons (2016-2021)
  • Table 313. Mexico Antibody Drug Conjugate Sales, by Conjugates Tons (2016-2021)
  • Table 314. Mexico Antibody Drug Conjugate Sales, by Linker Tons (2016-2021)
  • Table 315. Mexico Antibody Drug Conjugate Sales, by Route Of Administration Tons (2016-2021)
  • Table 316. Mexico Antibody Drug Conjugate Sales, by Indications Tons (2016-2021)
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Antibody Drug Conjugate: by Application(USD Million)
  • Table 328. Antibody Drug Conjugate Blood Cancer , by Region USD Million (2025-2030)
  • Table 329. Antibody Drug Conjugate Breast Cancer , by Region USD Million (2025-2030)
  • Table 330. Antibody Drug Conjugate Ovarian Cancer , by Region USD Million (2025-2030)
  • Table 331. Antibody Drug Conjugate Lung Cancer , by Region USD Million (2025-2030)
  • Table 332. Antibody Drug Conjugate Brain Tumor , by Region USD Million (2025-2030)
  • Table 333. Antibody Drug Conjugate: by Conjugates(USD Million)
  • Table 334. Antibody Drug Conjugate Small Molecules , by Region USD Million (2025-2030)
  • Table 335. Antibody Drug Conjugate Protein Toxin , by Region USD Million (2025-2030)
  • Table 336. Antibody Drug Conjugate Cytolytic Immunomodulatory Protein , by Region USD Million (2025-2030)
  • Table 337. Antibody Drug Conjugate Biologically Active Peptide , by Region USD Million (2025-2030)
  • Table 338. Antibody Drug Conjugate Enzymes , by Region USD Million (2025-2030)
  • Table 339. Antibody Drug Conjugate Radionuclides , by Region USD Million (2025-2030)
  • Table 340. Antibody Drug Conjugate: by Route Of Administration(USD Million)
  • Table 341. Antibody Drug Conjugate Enteral Route , by Region USD Million (2025-2030)
  • Table 342. Antibody Drug Conjugate Parenteral Route , by Region USD Million (2025-2030)
  • Table 343. Antibody Drug Conjugate: by Indications(USD Million)
  • Table 344. Antibody Drug Conjugate Breast Cancer , by Region USD Million (2025-2030)
  • Table 345. Antibody Drug Conjugate Lymphoma (Hl, Nhl, Alcl) , by Region USD Million (2025-2030)
  • Table 346. Antibody Drug Conjugate Leukemia (Aml, All) , by Region USD Million (2025-2030)
  • Table 347. Antibody Drug Conjugate Urothelial Cancer , by Region USD Million (2025-2030)
  • Table 348. Antibody Drug Conjugate Lung Cancer (Nsclc, SCLC), , by Region USD Million (2025-2030)
  • Table 349. Antibody Drug Conjugate Others , by Region USD Million (2025-2030)
  • Table 350. South America Antibody Drug Conjugate, by Country USD Million (2025-2030)
  • Table 351. South America Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 352. South America Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 353. South America Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 354. South America Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 355. South America Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 356. Brazil Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 357. Brazil Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 358. Brazil Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 359. Brazil Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 360. Brazil Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 361. Argentina Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 362. Argentina Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 363. Argentina Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 364. Argentina Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 365. Argentina Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 366. Rest of South America Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 367. Rest of South America Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 368. Rest of South America Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 369. Rest of South America Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 370. Rest of South America Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 371. Asia Pacific Antibody Drug Conjugate, by Country USD Million (2025-2030)
  • Table 372. Asia Pacific Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 373. Asia Pacific Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 374. Asia Pacific Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 375. Asia Pacific Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 376. Asia Pacific Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 377. China Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 378. China Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 379. China Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 380. China Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 381. China Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 382. Japan Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 383. Japan Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 384. Japan Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 385. Japan Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 386. Japan Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 387. India Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 388. India Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 389. India Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 390. India Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 391. India Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 392. South Korea Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 393. South Korea Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 394. South Korea Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 395. South Korea Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 396. South Korea Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 397. Taiwan Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 398. Taiwan Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 399. Taiwan Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 400. Taiwan Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 401. Taiwan Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 402. Australia Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 403. Australia Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 404. Australia Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 405. Australia Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 406. Australia Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 407. Rest of Asia-Pacific Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 408. Rest of Asia-Pacific Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 409. Rest of Asia-Pacific Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 410. Rest of Asia-Pacific Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 411. Rest of Asia-Pacific Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 412. Europe Antibody Drug Conjugate, by Country USD Million (2025-2030)
  • Table 413. Europe Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 414. Europe Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 415. Europe Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 416. Europe Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 417. Europe Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 418. Germany Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 419. Germany Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 420. Germany Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 421. Germany Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 422. Germany Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 423. France Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 424. France Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 425. France Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 426. France Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 427. France Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 428. Italy Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 429. Italy Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 430. Italy Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 431. Italy Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 432. Italy Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 433. United Kingdom Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 434. United Kingdom Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 435. United Kingdom Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 436. United Kingdom Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 437. United Kingdom Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 438. Netherlands Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 439. Netherlands Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 440. Netherlands Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 441. Netherlands Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 442. Netherlands Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 443. Rest of Europe Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 444. Rest of Europe Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 445. Rest of Europe Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 446. Rest of Europe Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 447. Rest of Europe Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 448. MEA Antibody Drug Conjugate, by Country USD Million (2025-2030)
  • Table 449. MEA Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 450. MEA Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 451. MEA Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 452. MEA Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 453. MEA Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 454. Middle East Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 455. Middle East Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 456. Middle East Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 457. Middle East Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 458. Middle East Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 459. Africa Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 460. Africa Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 461. Africa Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 462. Africa Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 463. Africa Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 464. North America Antibody Drug Conjugate, by Country USD Million (2025-2030)
  • Table 465. North America Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 466. North America Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 467. North America Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 468. North America Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 469. North America Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 470. United States Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 471. United States Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 472. United States Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 473. United States Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 474. United States Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 475. Canada Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 476. Canada Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 477. Canada Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 478. Canada Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 479. Canada Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 480. Mexico Antibody Drug Conjugate, by Application USD Million (2025-2030)
  • Table 481. Mexico Antibody Drug Conjugate, by Conjugates USD Million (2025-2030)
  • Table 482. Mexico Antibody Drug Conjugate, by Linker USD Million (2025-2030)
  • Table 483. Mexico Antibody Drug Conjugate, by Route Of Administration USD Million (2025-2030)
  • Table 484. Mexico Antibody Drug Conjugate, by Indications USD Million (2025-2030)
  • Table 485. Antibody Drug Conjugate Sales: by Application(Tons)
  • Table 486. Antibody Drug Conjugate Sales Blood Cancer , by Region Tons (2025-2030)
  • Table 487. Antibody Drug Conjugate Sales Breast Cancer , by Region Tons (2025-2030)
  • Table 488. Antibody Drug Conjugate Sales Ovarian Cancer , by Region Tons (2025-2030)
  • Table 489. Antibody Drug Conjugate Sales Lung Cancer , by Region Tons (2025-2030)
  • Table 490. Antibody Drug Conjugate Sales Brain Tumor , by Region Tons (2025-2030)
  • Table 491. Antibody Drug Conjugate Sales: by Conjugates(Tons)
  • Table 492. Antibody Drug Conjugate Sales Small Molecules , by Region Tons (2025-2030)
  • Table 493. Antibody Drug Conjugate Sales Protein Toxin , by Region Tons (2025-2030)
  • Table 494. Antibody Drug Conjugate Sales Cytolytic Immunomodulatory Protein , by Region Tons (2025-2030)
  • Table 495. Antibody Drug Conjugate Sales Biologically Active Peptide , by Region Tons (2025-2030)
  • Table 496. Antibody Drug Conjugate Sales Enzymes , by Region Tons (2025-2030)
  • Table 497. Antibody Drug Conjugate Sales Radionuclides , by Region Tons (2025-2030)
  • Table 498. Antibody Drug Conjugate Sales: by Route Of Administration(Tons)
  • Table 499. Antibody Drug Conjugate Sales Enteral Route , by Region Tons (2025-2030)
  • Table 500. Antibody Drug Conjugate Sales Parenteral Route , by Region Tons (2025-2030)
  • Table 501. Antibody Drug Conjugate Sales: by Indications(Tons)
  • Table 502. Antibody Drug Conjugate Sales Breast Cancer , by Region Tons (2025-2030)
  • Table 503. Antibody Drug Conjugate Sales Lymphoma (Hl, Nhl, Alcl) , by Region Tons (2025-2030)
  • Table 504. Antibody Drug Conjugate Sales Leukemia (Aml, All) , by Region Tons (2025-2030)
  • Table 505. Antibody Drug Conjugate Sales Urothelial Cancer , by Region Tons (2025-2030)
  • Table 506. Antibody Drug Conjugate Sales Lung Cancer (Nsclc, SCLC), , by Region Tons (2025-2030)
  • Table 507. Antibody Drug Conjugate Sales Others , by Region Tons (2025-2030)
  • Table 508. South America Antibody Drug Conjugate Sales, by Country Tons (2025-2030)
  • Table 509. South America Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 510. South America Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 511. South America Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 512. South America Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 513. South America Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 514. Brazil Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 515. Brazil Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 516. Brazil Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 517. Brazil Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 518. Brazil Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 519. Argentina Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 520. Argentina Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 521. Argentina Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 522. Argentina Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 523. Argentina Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 524. Rest of South America Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 525. Rest of South America Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 526. Rest of South America Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 527. Rest of South America Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 528. Rest of South America Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 529. Asia Pacific Antibody Drug Conjugate Sales, by Country Tons (2025-2030)
  • Table 530. Asia Pacific Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 531. Asia Pacific Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 532. Asia Pacific Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 533. Asia Pacific Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 534. Asia Pacific Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 535. China Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 536. China Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 537. China Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 538. China Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 539. China Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 540. Japan Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 541. Japan Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 542. Japan Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 543. Japan Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 544. Japan Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 545. India Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 546. India Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 547. India Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 548. India Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 549. India Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 550. South Korea Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 551. South Korea Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 552. South Korea Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 553. South Korea Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 554. South Korea Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 555. Taiwan Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 556. Taiwan Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 557. Taiwan Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 558. Taiwan Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 559. Taiwan Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 560. Australia Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 561. Australia Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 562. Australia Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 563. Australia Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 564. Australia Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 565. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 566. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 567. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 568. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 569. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 570. Europe Antibody Drug Conjugate Sales, by Country Tons (2025-2030)
  • Table 571. Europe Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 572. Europe Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 573. Europe Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 574. Europe Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 575. Europe Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 576. Germany Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 577. Germany Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 578. Germany Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 579. Germany Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 580. Germany Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 581. France Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 582. France Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 583. France Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 584. France Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 585. France Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 586. Italy Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 587. Italy Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 588. Italy Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 589. Italy Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 590. Italy Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 591. United Kingdom Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 592. United Kingdom Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 593. United Kingdom Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 594. United Kingdom Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 595. United Kingdom Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 596. Netherlands Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 597. Netherlands Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 598. Netherlands Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 599. Netherlands Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 600. Netherlands Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 601. Rest of Europe Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 602. Rest of Europe Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 603. Rest of Europe Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 604. Rest of Europe Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 605. Rest of Europe Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 606. MEA Antibody Drug Conjugate Sales, by Country Tons (2025-2030)
  • Table 607. MEA Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 608. MEA Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 609. MEA Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 610. MEA Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 611. MEA Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 612. Middle East Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 613. Middle East Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 614. Middle East Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 615. Middle East Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 616. Middle East Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 617. Africa Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 618. Africa Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 619. Africa Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 620. Africa Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 621. Africa Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 622. North America Antibody Drug Conjugate Sales, by Country Tons (2025-2030)
  • Table 623. North America Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 624. North America Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 625. North America Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 626. North America Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 627. North America Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 628. United States Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 629. United States Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 630. United States Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 631. United States Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 632. United States Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 633. Canada Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 634. Canada Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 635. Canada Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 636. Canada Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 637. Canada Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 638. Mexico Antibody Drug Conjugate Sales, by Application Tons (2025-2030)
  • Table 639. Mexico Antibody Drug Conjugate Sales, by Conjugates Tons (2025-2030)
  • Table 640. Mexico Antibody Drug Conjugate Sales, by Linker Tons (2025-2030)
  • Table 641. Mexico Antibody Drug Conjugate Sales, by Route Of Administration Tons (2025-2030)
  • Table 642. Mexico Antibody Drug Conjugate Sales, by Indications Tons (2025-2030)
  • Table 643. Research Programs/Design for This Report
  • Table 644. Key Data Information from Secondary Sources
  • Table 645. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antibody Drug Conjugate: by Application USD Million (2016-2021)
  • Figure 5. Global Antibody Drug Conjugate: by Conjugates USD Million (2016-2021)
  • Figure 6. Global Antibody Drug Conjugate: by Route Of Administration USD Million (2016-2021)
  • Figure 7. Global Antibody Drug Conjugate: by Indications USD Million (2016-2021)
  • Figure 8. South America Antibody Drug Conjugate Share (%), by Country
  • Figure 9. Asia Pacific Antibody Drug Conjugate Share (%), by Country
  • Figure 10. Europe Antibody Drug Conjugate Share (%), by Country
  • Figure 11. MEA Antibody Drug Conjugate Share (%), by Country
  • Figure 12. North America Antibody Drug Conjugate Share (%), by Country
  • Figure 13. Global Antibody Drug Conjugate: by Application Tons (2016-2021)
  • Figure 14. Global Antibody Drug Conjugate: by Conjugates Tons (2016-2021)
  • Figure 15. Global Antibody Drug Conjugate: by Route Of Administration Tons (2016-2021)
  • Figure 16. Global Antibody Drug Conjugate: by Indications Tons (2016-2021)
  • Figure 17. South America Antibody Drug Conjugate Share (%), by Country
  • Figure 18. Asia Pacific Antibody Drug Conjugate Share (%), by Country
  • Figure 19. Europe Antibody Drug Conjugate Share (%), by Country
  • Figure 20. MEA Antibody Drug Conjugate Share (%), by Country
  • Figure 21. North America Antibody Drug Conjugate Share (%), by Country
  • Figure 22. Global Antibody Drug Conjugate share by Players 2021 (%)
  • Figure 23. Global Antibody Drug Conjugate share by Players (Top 3) 2021(%)
  • Figure 24. Global Antibody Drug Conjugate share by Players (Top 5) 2021(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer (United States) Revenue: by Geography 2021
  • Figure 28. Progenics Pharmaceuticals(United States) Revenue, Net Income and Gross profit
  • Figure 29. Progenics Pharmaceuticals(United States) Revenue: by Geography 2021
  • Figure 30. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Novartis (Switzerland) Revenue: by Geography 2021
  • Figure 32. Eli Lilly(United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lilly(United States) Revenue: by Geography 2021
  • Figure 34. Genentech(United States) Revenue, Net Income and Gross profit
  • Figure 35. Genentech(United States) Revenue: by Geography 2021
  • Figure 36. Genmab (Denmark) Revenue, Net Income and Gross profit
  • Figure 37. Genmab (Denmark) Revenue: by Geography 2021
  • Figure 38. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 39. Amgen (United States) Revenue: by Geography 2021
  • Figure 40. Bayer HealthCare (Germany) Revenue, Net Income and Gross profit
  • Figure 41. Bayer HealthCare (Germany) Revenue: by Geography 2021
  • Figure 42. Celldex Therapeutics(United States) Revenue, Net Income and Gross profit
  • Figure 43. Celldex Therapeutics(United States) Revenue: by Geography 2021
  • Figure 44. Concortis Biotherapeutics(United States) Revenue, Net Income and Gross profit
  • Figure 45. Concortis Biotherapeutics(United States) Revenue: by Geography 2021
  • Figure 46. Global Antibody Drug Conjugate: by Application USD Million (2025-2030)
  • Figure 47. Global Antibody Drug Conjugate: by Conjugates USD Million (2025-2030)
  • Figure 48. Global Antibody Drug Conjugate: by Route Of Administration USD Million (2025-2030)
  • Figure 49. Global Antibody Drug Conjugate: by Indications USD Million (2025-2030)
  • Figure 50. South America Antibody Drug Conjugate Share (%), by Country
  • Figure 51. Asia Pacific Antibody Drug Conjugate Share (%), by Country
  • Figure 52. Europe Antibody Drug Conjugate Share (%), by Country
  • Figure 53. MEA Antibody Drug Conjugate Share (%), by Country
  • Figure 54. North America Antibody Drug Conjugate Share (%), by Country
  • Figure 55. Global Antibody Drug Conjugate: by Application Tons (2025-2030)
  • Figure 56. Global Antibody Drug Conjugate: by Conjugates Tons (2025-2030)
  • Figure 57. Global Antibody Drug Conjugate: by Route Of Administration Tons (2025-2030)
  • Figure 58. Global Antibody Drug Conjugate: by Indications Tons (2025-2030)
  • Figure 59. South America Antibody Drug Conjugate Share (%), by Country
  • Figure 60. Asia Pacific Antibody Drug Conjugate Share (%), by Country
  • Figure 61. Europe Antibody Drug Conjugate Share (%), by Country
  • Figure 62. MEA Antibody Drug Conjugate Share (%), by Country
  • Figure 63. North America Antibody Drug Conjugate Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Progenics Pharmaceuticals(United States)
  • Novartis (Switzerland)
  • Eli Lilly(United States)
  • Genentech(United States)
  • Genmab (Denmark)
  • Amgen (United States)
  • Bayer HealthCare (Germany)
  • Celldex Therapeutics(United States)
  • Concortis Biotherapeutics(United States)
Additional players considered in the study are as follows:
Mersana Therapeutics(United States) , Millennium Pharmaceuticals(United States) , AbbVie (United States) , Agensys(United States)
Select User Access Type

Key Highlights of Report


Jan 2024 237 Pages 74 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antibody Drug Conjugate research Quantitative research analysis
Global Antibody Drug Conjugate research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer (United States), Progenics Pharmaceuticals(United States), Novartis (Switzerland), Eli Lilly(United States), Genentech(United States), Genmab (Denmark), Amgen (United States), Bayer HealthCare (Germany), Celldex Therapeutics(United States) and Concortis Biotherapeutics(United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Emergence Of Cancer Treatment Options" is seen as one of major influencing trends for Antibody Drug Conjugate Market during projected period 2021-2030.
The Antibody Drug Conjugate market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Antibody Drug Conjugate research Report?

Have a Query? Click Here

Other Related Reports

Acne Medication Comprehensive Study by Type (Injection, Oral), Application (Hospital, Clinic) Players and Region - Global Market Outlook to 2028
$ 3500
Betamethasone Ointment Comprehensive Study by Type (Betamethasone Dipropionate, Betamethasone Sodium Phosphate, Betamethasone Valerate), Application (Eczema, Dermatitis, Allergies, Rash), Distributio...
$ 3450
Sulfachloropyridazine Sodium Comprehensive Study by Type (Concentration: <10% , Concentration: 10%-20%), Application (Escherichia Coli Infection Treatment , Staphylococcal Infection Treatment), Route...
$ 3750
Clozapine Comprehensive Study by Application (Hospital, Clinic, Home Care), Distribution Channel (Online Retail, Offline Retail), Form (Tablet, Liquid) Players and Region - Global Market Outlook to ...
$ 3500
Compounding Pharmacy Comprehensive Study by Type (Oral (Capsules, Tablets, suspensions, lozenges, lollipops), Topical (Cream, gel, ointments, lotions), Mouthwashes, Suppositories, Injectables (Inject...
$ 3750
Antiemetic Drugs Comprehensive Study by Type (Dopamine Antagonist, 5-HT-3 Receptor Antagonist, NK1 Receptor Antagonist, Cannabinoid Receptor Antagonist), Application (Chemotherapy, Gastroenteritis, S...
$ 3450